Lek, a Sandoz company, recognized for its work-life integration efforts
- Lek, a Sandoz company, is continuously striving to improve work-life balance among employees.
- Lek, a Sandoz company, has been involved in the Family Friendly Company initiative from the very beginning and is among the first recipients of a full certificate in Slovenia.
Lek, a Sandoz company, continues to hold the full certificate Family Friendly Company which they received as one of the first companies in Slovenia in 2007. The extension of the certificate confirms the commitment of Lek, a Sandoz company, to establish a family friendly work environment which contributes to greater satisfaction and loyalty of employees. The certificate is awarded by a non-governmental organisation Ekvilib Institute.
Lek, a Sandoz company, has joined the Family Friendly Company initiative from the very beginning. The first set of actions was launched in 2007 as a part of the basic Family Friendly Company certificate; three years later however, as one of the first companies in Slovenia, they upgraded the basic certificate with a full certificate.
»Maintaining the existing and the introduction of new family-friendly actions is a continuous process which actively involves our associates. These actions are adopted on the initiative and with the support of our employees. Here we pay special attention to the fact that all the actions taken are actually executed« said Katarina Klemenc, Head of Diversity and Inclusion at Lek, a Sandoz company, upon the successful extension of the full Family Friendly Company certificate. »We want to help our employees with work-life integration as we want to be an employer of choice for employees with families. This concept determines an important part of our responsibility to employees therefore it also constitutes a part of our annual performance review with employees and their individual career development plan.«
Lek, a Sandoz company, has adopted a series of family-friendly actions over the past six years, such as flexible work hours with a choice of arrival and departure time at the workplace, a time account, the option of working from home, re-integration of employees into work after maternity or parental leave, company open house days for families of employees, schoolchildren day care and leisure activities for children during school holidays. Last year, a new measure was adopted – the child’s time bonus – which enables parents to take a day off when introducing children to a school or nursery.
Additional benefits are also available to employees, including the Lek kindergarten in Ljubljana, the opportunity of vacationing in one of the company’s holiday homes, a fitness studio and health clinic at the company headquarters in Ljubljana, as well as further training and education.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry Sandoz offers a broad range of about 1, 100 high-quality, affordable products that are no longer protected by patents. With nearly 26,000 employees in approximately 140 countries, Sandoz holds the #1 position globally in biosimilars, injectables, ophthalmics and dermatology as well as a strong global #5 position in inhalables. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US). In 2012, Sandoz posted sales of USD 8.7 billion. For more information, please visit www.sandoz.com.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32